← Eichor
Study identifier: NCT06006273 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

Condition: Refractory Solid Tumors  ·  Sponsor: M.D. Anderson Cancer Center

PhasePhase 1
Planned participants48
Who can joinAll sexes, 1 Year to 25 Years
Healthy volunteersNo

About this study

To find the recommended dose of eribulin that can be given in combination with irinotecan and temozolomide to treat relapsed and/or refractory solid tumors.

This description comes directly from the study's public registry record.

Talk to the study team

Fiorela Hernandez Tejada, MD  ·  (832) 306-9802  ·  fnhernandez@mdanderson.org

Always discuss trial participation with your own doctor first.

Locations (1)

M D Anderson Cancer CenterHouston, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06006273